RARE - Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
2024-06-12 07:00:18 ET
More on Mereo BioPharma, Ultragenyx, etc.
- Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
- Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript
- Mereo BioPharma's Pipeline Promise Vs. Valuation And Market Realities
- Ultragenyx upped at Goldman Sachs on bone disorder treatment
- Ultragenyx Phase 3 study for DTX401 meets primary endpoint